About 

Dernières nouvelles pour Uber Technologies (NYSE:UBER) Stock

UBER TECHNOLOGIES INC

Uber Technologies

Uber Technologies is a technology provider that matches riders with drivers, hungry people with restaurants and food couriers, and shippers with carriers. The firm's on-demand technology platform is currently utilized by traditional cars as well as autonomous vehicles, but could eventually be used for additional products and services, such as delivery via drones or electronic vehicle take-off and landing (eVTOL) technology. Uber operates in over 70 countries, with over 170 million users who order rides or food at least once a month.

Uber Technologies Inc

<p>Wells Fargo  analyst Michael Brown   maintains Moelis (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MC#NYSE">MC</a>) with a Equal-Weight and raises the price target from $50 to $64.</p>


News

Price Target

Analyst Ratings

Wells Fargo Maintains Equal-Weight on Moelis, Raises Price Target to $64

<p><a href="https://www.youtube.com/watch?v=1c1dgLqTlvc">https://www.youtube.com/watch?v=1c1dgLqTlvc</a></p>


Macro Notification

Politics

Economics

General

President Trump Says He Will Speak To Brazilian President At Some Point

<p><strong>Gorilla Technology Group Inc.</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GRRR#NASDAQ">GRRR</a>) delivered a <a target="_blank" href="https://www.benzinga.com/pressreleases/25/07/46364113/gorilla-provides-business-updates" rel="noreferrer noopener">comprehensive business update</a> on Friday, showcasing a robust global pipeline, expanded strategic partnerships, and a strengthened financial foundation.</p>
<p>Gorilla reported 87 active opportunities valued at $5.6 billion and aims to secure $1.3 billion in long-term contracts by mid-2026. Several high-value deals are in the final negotiation or MOU stage, signaling near-term conversions.</p>
<p>Gorilla <a target="_blank" href="https://www.benzinga.com/trading-ideas/movers/25/07/46348352/gorilla-technology-shares-plunge-after-nvidia-fueled-rally-reverses" rel="noreferrer noopener">announced</a> it is now an official solutions provider for <strong>NVIDIA Corp.</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>), enhancing its existing partnership with <strong>Hewlett-Packard Enterprise Co.</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HPE#NYSE">HPE</a>).</p>
<p><strong><em>Also Read: <a target="_blank" href="https://www.benzinga.com/trading-ideas/movers/25/06/46075366/gorilla-technology-grrr-stock-surges-on-agreement-to-acquire-thai-ai-firms" rel="noreferrer noopener">Gorilla Technology (GRRR) Stock Surges On Agreement To Acquire Thai AI Firms</a></em></strong></p>
<p>These relationships help strengthen Gorilla&#8217;s position in government infrastructure and smart city deployments by integrating advanced AI capabilities.</p>
<p>In the U.S., Gorilla is pursuing East Coast infrastructure and public safety projects. It also plans to close the acquisition of a U.S.-based AI company this quarter, adding 70 employees to its workforce.</p>
<p>In Southeast Asia, the company is finalizing a landmark education tech deployment in Thailand, impacting over 6.5 million students.</p>
<p>Gorilla&#8217;s &#8220;ONE AMAZON&#8221; program will debut at New York Climate Week in September, with revenue anticipated in the fourth quarter of 2025.</p>
<p>The company&#8217;s TerraStrata platform, managing $3.5 billion in assets, has begun deploying capital into global infrastructure initiatives.</p>
<p>Gorilla recently <a target="_blank" href="https://www.benzinga.com/trading-ideas/movers/25/07/46348352/gorilla-technology-shares-plunge-after-nvidia-fueled-rally-reverses" rel="noreferrer noopener">completed</a> a $105 million equity raise, boosting its cash reserves to $108 million with $16.5 million in low-interest debt.</p>
<p>The financing, designed to reduce dilution, supports the company&#8217;s obligations tied to large-scale government contracts. Additionally, $200 million in secured term sheets and non-dilutive funding remain accessible.</p>
<p>Related ETFs include <strong>the Global X Artificial Intelligence &amp; Technology ETF </strong>(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AIQ#NASDAQ">AIQ</a>) and <strong>the ROBO Global Robotics and Automation Index ETF</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ROBO#NYSE">ROBO</a>).</p>
<p><strong>Price Action: </strong>GRRR shares are trading lower by 0.09% to $21.08 at last check Friday.</p>
<p><strong>Read Next:</strong></p>
<ul class="wp-block-list">
<li><strong><em><a href="https://www.benzinga.com/analyst-stock-ratings/analyst-color/25/07/46353542/palantir-next-oracle-trump-backed-ai-surge" target="_blank" rel="noreferrer noopener">Palantir Is The &#8216;Next Oracle&#8217; On Trump-Backed AI Surge: Analyst</a></em></strong></li>
</ul>
<p><em>Photo via Shutterstock</em></p>


Tech

GRRR

NVDA

ROBO

Gorilla Technology Targets $1.3 Billion In New Contracts By Mid-2026

<p>Wells Fargo  analyst Michael Brown   maintains Lazard (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LAZ#NYSE">LAZ</a>) with a Equal-Weight and raises the price target from $38 to $50.</p>


Wells Fargo Maintains Equal-Weight on Lazard, Raises Price Target to $50

<p>B. Riley Securities  analyst Craig Ellis   maintains Alpha &amp; Omega (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AOSL#NASDAQ">AOSL</a>) with a Buy and raises the price target from $30 to $35.</p>


AOSL

B. Riley Securities Maintains Buy on Alpha & Omega, Raises Price Target to $35

<p>Wells Fargo  analyst Michael Brown   maintains LPL Finl Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LPLA#NASDAQ">LPLA</a>) with a Overweight and raises the price target from $402 to $420.</p>


LPLA

Wells Fargo Maintains Overweight on LPL Finl Hldgs, Raises Price Target to $420

<p>Wells Fargo  analyst Michael Brown   maintains Houlihan Lokey (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HLI#NYSE">HLI</a>) with a Overweight and raises the price target from $185 to $209.</p>


Wells Fargo Maintains Overweight on Houlihan Lokey, Raises Price Target to $209

<p>Truist Securities  analyst Michael Ciarmoli   maintains Woodward (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WWD#NASDAQ">WWD</a>) with a Buy and raises the price target from $267 to $294.</p>


Truist Securities Maintains Buy on Woodward, Raises Price Target to $294

<p>Wells Fargo  analyst Michael Brown   maintains Evercore (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EVR#NYSE">EVR</a>) with a Equal-Weight and raises the price target from $194 to $282.</p>


Wells Fargo Maintains Equal-Weight on Evercore, Raises Price Target to $282

<p>Wells Fargo  analyst Michael Brown   maintains Carlyle Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CG#NASDAQ">CG</a>) with a Equal-Weight and raises the price target from $49 to $61.</p>


Wells Fargo Maintains Equal-Weight on Carlyle Group, Raises Price Target to $61

<p>Truist Securities  analyst Michael Ciarmoli   maintains Curtiss-Wright (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CW#NYSE">CW</a>) with a Hold and lowers the price target from $356 to $338.</p>


Truist Securities Maintains Hold on Curtiss-Wright, Lowers Price Target to $338

<p>Wells Fargo  analyst Michael Brown   maintains TPG (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TPG#NASDAQ">TPG</a>) with a Overweight and raises the price target from $58 to $62.</p>


Wells Fargo Maintains Overweight on TPG, Raises Price Target to $62

<p>Truist Securities  analyst Michael Ciarmoli   maintains Lockheed Martin (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LMT#NYSE">LMT</a>) with a Buy and lowers the price target from $579 to $554.</p>


Truist Securities Maintains Buy on Lockheed Martin, Lowers Price Target to $554

<p><figure class="wp-block-image size-large"><img loading="lazy" decoding="async" width="1024" height="678" src="https://contributor-assets.benzinga.com/wp-content/uploads/2025/07/09011117/IonQ-Ion-MGT-Trap-1024x678.jpg" alt="" class="wp-image-15509" srcset="https://contributor-assets.benzinga.com/wp-content/uploads/2025/07/09011117/IonQ-Ion-MGT-Trap-1024x678.jpg 1024w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/07/09011117/IonQ-Ion-MGT-Trap-300x199.jpg 300w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/07/09011117/IonQ-Ion-MGT-Trap-768x509.jpg 768w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/07/09011117/IonQ-Ion-MGT-Trap.jpg 1200w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure></p>
<p><strong>Trapped-ion computing processor. Used with permission: IonQ.</strong></p>
<p>Quantum computing has arrived. IonQ (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IONQ#NYSE">IONQ</a>), a leading commercial quantum computing and networking company, is shipping quantum computers and networks, growing at an almost 100% YoY pace, as well as selling and winning deals at over $44 a share. Ironically, it seems that the market hasn't fully grasped that yet. They're still thinking of massive lab prototypes and expensive sub-Kelvin dilution refrigerators, while IonQ is bringing live systems to paying customers worldwide.</p>
<h2 class="wp-block-heading"><strong>Selling full quantum systems, while scaling from the cloud to the planet</strong></h2>
<p>IonQ systems run on AWS Braket, Azure Quantum and Google Quantum AI Cloud. That makes at least three major public clouds. No other quantum vendor matches that reach. Through its strategic organic and inorganic expansion, IonQ operates in Asia, EU, Canada, UK and America. That global network footprint isn't experimental. The company&#8217;s commercial infrastructure leverages hyperscalers, telecom and defense-adjacent applications.</p>
<p>And they didn't stumble into this, they systematically assembled it. They <a href="https://ionq.com/news/ionq-completes-acquisition-of-lightsynq-accelerating-quantum-computing-and">bought Lightsynq in June</a> to further expand their photonic interconnect and quantum memory capabilities. "With this acquisition, we're accelerating our development timeline to fault tolerant quantum computers and long distance networking capabilities," CEO Niccolo de Masi said during an exclusive interview.</p>
<p>The acquired Lightsync technology allows IonQ to provide optimized compute capabilities over thousands of kilometers. He said Lightsynq latency shifts from about 55 milliseconds to two seconds, which is a 97% improvement, letting entanglement persist long enough for even more complex real-world applications to run. That's not hypothetical puffery, it's architectural muscularity.</p>
<p>They also inked a <a href="https://ionq.com/news/ionq-announces-usd22m-deal-with-epb-establishing-chattanooga-tennessee-as">$22 million deal with EPB </a>to establish a quantum hub in Chattanooga offering Forte Enterprise and networking training for grid optimization. That marks the first U.S. quantum computing and networking center complete with a new IonQ office.</p>
<h2 class="wp-block-heading"><strong>This is an acquisition spree with strategy</strong></h2>
<p>In addition to buying Lightsynq, IonQ is now the majority shareholder of <a href="https://ionq.com/news/ionq-to-acquire-id-quantique-enter-into-strategic-partnership-with-sk">ID Quantique</a> to beef up their Swiss-grade quantum networking capabilities. They announced the <a href="https://ionq.com/news/ionq-announces-plans-for-first-space-based-quantum-key-distribution-network">Capella Space</a> acquisition to take quantum key distribution systems into orbit, creating a secure satellite-ground quantum internet. Most recently they agreed to <a href="https://ionq.com/news/ionq-announces-agreement-to-acquire-oxford-ionics-accelerating-path-to-pioneering">buy Oxford Ionics for $1.075 billion</a>, gaining OI&#8217;s complementary ion-trap breakthrough tech and UK R&amp;D depth.</p>
<p>Add it up. They're assembling compute, memory, networking, satellite and cloud access into one commercial platform. That's a full tech stack, vertically integrated. IonQ is one of the biggest, if not the biggest, public-quantum movers by acquisition count with an IP portfolio of almost 1000 owned and controlled patents.</p>
<h2 class="wp-block-heading"><strong>AQ is the metric that actually matters</strong></h2>
<p>IonQ talks algorithmic qubits, AQ, rather than inflated raw qubit counts. Their Forte and Forte Enterprise quantum systems hit AQ 36. While the next-gen Tempo quantum systems will target AQ 64 by the end of 2025.</p>
<p>"AQ 64 is an important milestone for our industry. Even a data center packed with classical GPUs couldn't keep up with a single AQ 64 machine when trying to exactly simulate its quantum circuits. Especially for small-scale versions of factoring, decryption, optimization or linear-algebra workloads,&#8221; explained  de Masi.</p>
<p>AQ signals usable compute power, not just hardware specs. It integrates error rates, fidelity, connectivity and circuit depth. It's performance that users can build with. And they're already delivering. </p>
<p>Software simulation leader Ansys saw a <a href="https://www.iotworldtoday.com/quantum/medical-engineering-simulations-accelerated-12-by-quantum-computer">12% speed-up on heart-pump simulations</a>, and IonQ&#8217;s work with AstraZeneca, AWS and Nvidia <a href="https://thequantuminsider.com/2025/06/09/ionq-speeds-quantum-accelerated-drug-development-application-in-partnership-with-astrazeneca-aws-and-nvidia/">cut drug-discovery interference times by 20x</a>. These are real customer benchmarks.</p>
<p><figure class="wp-block-image size-large"><img loading="lazy" decoding="async" width="1024" height="683" src="https://contributor-assets.benzinga.com/wp-content/uploads/2025/07/09011514/Nicco-de-Masi_022625_001-Edit-1-1024x683.jpg" alt="" class="wp-image-15511" srcset="https://contributor-assets.benzinga.com/wp-content/uploads/2025/07/09011514/Nicco-de-Masi_022625_001-Edit-1-1024x683.jpg 1024w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/07/09011514/Nicco-de-Masi_022625_001-Edit-1-300x200.jpg 300w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/07/09011514/Nicco-de-Masi_022625_001-Edit-1-768x512.jpg 768w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/07/09011514/Nicco-de-Masi_022625_001-Edit-1.jpg 1200w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure></p>
<p>Niccolo de Masi, IonQ CEO and Cambridge-trained physicist. Used with permission: IonQ.</p>
<h2 class="wp-block-heading"><strong>Quantum networking is the subplot few are pricing in</strong></h2>
<p>Compute grabs headlines. Networking unlocks scale. IonQ leads here. "We are the only public quantum networking company in the world," de Masi said.</p>
<p>IonQ is building quantum repeaters via Lightsynq. Capella Space extends links to satellites and back to earth. EPB in Tennessee gives grid-scale metropolitan hubs. ID Quantique expands the quantum networking capabilities and backbone. That adds up to a real quantum internet. Encryption, finance, defense and satellite operations are all sectors IonQ is positioning to serve through secure networks.</p>
<p>"We have an exceptional opportunity to accelerate our vision for the quantum internet through our announced acquisitions of LightSynq and Capella," De Masi said. That's ambition backed by capital and hardware.</p>
<h2 class="wp-block-heading"><strong>Miniaturization and energy-efficient design</strong></h2>
<p>Quantum systems usually require bulky cryogenic setups. IonQ has been pushing room-temperature, vacuum-less parts that reduce weight, cost and power use. They're moving toward modular, replaceable components that match data center readiness. It's also about building a compute, networking and applications ecosystem smartly, not just building massive server farms with extreme climate controls and state-mandated, co-located power stations.</p>
<p>"This is the quantum computing industry, not the quantum construction business. Never in the history of computing has anything other than smaller and cheaper won. Additionally, quantum computers run on a fraction of the electricity of classical supercomputers, and <a href="https://theconversation.com/could-energy-efficiency-be-quantum-computers-greatest-strength-yet-191989">in some instances quantum is 100x more energy efficient</a> than traditional compute, " de Masi said.</p>
<p>That's not theoretical. It's operational.</p>
<p><figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="576" src="https://contributor-assets.benzinga.com/wp-content/uploads/2025/07/09011643/Tori-Carey-in-CP-3-1024x576.jpg" alt="" class="wp-image-15513" style="width:920px;height:auto" srcset="https://contributor-assets.benzinga.com/wp-content/uploads/2025/07/09011643/Tori-Carey-in-CP-3-1024x576.jpg 1024w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/07/09011643/Tori-Carey-in-CP-3-300x169.jpg 300w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/07/09011643/Tori-Carey-in-CP-3-768x432.jpg 768w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/07/09011643/Tori-Carey-in-CP-3.jpg 1200w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure></p>
<p>IonQ engineer holding a test wafer of dozens of quantum processors. Used with permission: IonQ.</p>
<h2 class="wp-block-heading"><strong>Financial strength and capital to execute</strong></h2>
<p>IonQ recently <a href="https://finance.yahoo.com/news/ionq-announces-pricing-1-0-125500938.html">priced a $1 billion equity raise</a> at $55.49 a share, that&#8217;s more than a 25% premium over the prior market closing price, lifting cash to $1.68 billion. That's one of the largest single-investor deals in quantum history. <a href="https://finance.yahoo.com/news/ionq-price-target-raised-55-122507534.html">Benchmark</a> and <a href="https://investorsobserver.com/news/stock-update/priced-for-the-future-ionq-can-grow-into-quantum-premium-analyst-says/#:~:text=That's%20one%20of%20the%20main,capitalization%20of%20approximately%20$11.5%20billion.">Cantor</a> called it confirmation of IonQ's differentiated commercial model across hardware, services and applications.</p>
<p>While still pursuing profitability, its Q1 revenue came in above guidance. Cash sat at nearly $750 million. Hyundai, Airbus, Air Force Research Lab, EPB, University of Maryland and AWS are all paying or paid to use IonQ's the tech. Based on IonQ's earnings disclosures and expansion activity, the capital appears targeted toward scaling compute, networking and commercial systems.</p>
<h2 class="wp-block-heading"><strong>The entire company is its competitive moat</strong></h2>
<p>IonQ is unique within the pure-play quantum computing space. Acquisitions, cloud reach, engineering, hardware, networking, satellite and workforce hubs. Patent depth. Customer results. Cash. Its technical roadmap.</p>
<p>"Every day we get up in the morning knowing that we can impact every area of applied science," De Masi told me. "Whether it's drug discovery or defense and intelligence or logistics or material science, we impact everything."</p>
<p>IonQ's execution speaks louder than its pure-play quantum computing competitors. That's what sets them apart.</p>
<h2 class="wp-block-heading">Do your own research, you&#8217;ll see what the &#8220;smart money&#8221; sees</h2>
<p>These are obviously personal opinions; not financial advice. Anyone considering investing in any asset needs to do their own research and understand the risks associated with emerging tech such as quantum computing. While I no longer own any shares of IonQ, when I sold my entire stake in mid-December 2024 I turned a 340% profit. That was the best performing equity asset in my portfolio. And based on all the publicly available information about this company; it&#8217;s still a banger with room to run.</p>
<p>The latest sale to <a href="https://finance.yahoo.com/news/ionq-announces-pricing-1-0-125500938.html">Heights Capital Management of more than 14 million IonQ shares</a> at a 25% markup with the seven-year option of buying another 36 million shares at $99.88 each is a resounding vote of confidence from Wall Street sharps regarding IonQ&#8217;s potential upside.</p>
<p>Quantum isn't five years away. It's crossing into reality with commercial contracts, live networks and satellite integration underway. IonQ is the stock that reflects that. Not early-stage theory. Not hype. Just results.</p>



Equities

Long Ideas

Opinion

IONQ

Why IonQ Is My Top Stock Pick For 2025

<p>Walgreens Boots Alliance, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WBA#NASDAQ">WBA</a>) (the "Company" or "WBA") today announced that at the Company's Special Meeting of Shareholders (the "Special Meeting"), WBA shareholders approved the previously announced acquisition of the Company by entities affiliated with Sycamore Partners Management, L.P. ("Sycamore").</p>
<p>According to the preliminary results, approximately 96% of votes cast at the Special Meeting by all shareholders were voted in favor of the merger agreement proposal. In addition, approximately 95% of the votes cast at the Special Meeting by unaffiliated shareholders were voted in favor of the merger agreement proposal.</p>
<p>As previously announced on March 6, 2025, under the terms of the Merger Agreement, WBA shareholders will receive $11.45 per share in cash at closing, and one non-transferable Divested Asset Proceeds Right to receive up to an additional $3.00 in cash per share from the future monetization of WBA's debt and equity interests in VillageMD, which includes the Village Medical, Summit Health and CityMD businesses.</p>
<p>WBA expects to close the transaction in the third or fourth quarter of calendar year 2025, subject to customary closing conditions, including the receipt of required regulatory approvals.</p>


Walgreens Boots Alliance Shareholders Approve Acquisition Of The Company By Entities Affiliated With Sycamore Partners Management; Transaction Expected To Close in Q3 or Q4 Of CY25

<p>Simulations Plus (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SLP#NASDAQ">SLP</a>) is gearing up to announce its quarterly earnings on Monday, 2025-07-14. Here's a quick overview of what investors should know before the release.</p>
<p>Analysts are estimating that Simulations Plus will report an <strong>earnings per share</strong> (EPS) of $0.26.</p>
<p>The market awaits Simulations Plus's announcement, with hopes high for news of surpassing estimates and providing upbeat guidance for the next quarter.</p>
<p>It's important for new investors to understand that guidance can be a significant driver of stock prices.</p>
<h3>Historical Earnings Performance</h3>
<p>Last quarter the company beat EPS by $0.05, which was followed by a 7.83% increase in the share price the next day.</p>
<p>Here's a look at Simulations Plus's past performance and the resulting price change:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q2 2025</strong></th>
<th><strong>Q1 2025</strong></th>
<th><strong>Q4 2024</strong></th>
<th><strong>Q3 2024</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>0.26</td>
<td>0.17</td>
<td>0.03</td>
<td>0.15</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>0.31</td>
<td>0.17</td>
<td>0.06</td>
<td>0.19</td>
</tr>
<tr>
<td><strong>Price Change %</strong></td>
<td>8.0%</td>
<td>-7.000000000000001%</td>
<td>-9.0%</td>
<td>-15.0%</td>
</tr>
</tbody>
</table>
</p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1752242497_0.png" alt="eps graph" /></p>
<h3>Simulations Plus Share Price Analysis</h3>
<p>Shares of Simulations Plus were trading at $17.57 as of July 10. Over the last 52-week period, shares are down 58.91%. Given that these returns are generally negative, long-term shareholders are likely a little upset going into this earnings release. </p>
<h3>Analysts' Take on Simulations Plus</h3>
<p>Understanding market sentiments and expectations within the industry is crucial for investors. This analysis delves into the latest insights on Simulations Plus.</p>
<p>The consensus rating for Simulations Plus is Buy, derived from 3 analyst ratings. An average one-year price target of $33.67 implies a potential 91.63% upside.</p>
<h3>Peer Ratings Comparison</h3>
<p>This comparison focuses on the analyst ratings and average 1-year price targets of Health Catalyst, Definitive Healthcare and OptimizeRx, three major players in the industry, shedding light on their relative performance expectations and market positioning.</p>
<ul>
<li>Analysts currently favor an Buy trajectory for Health Catalyst, with an average 1-year price target of $6.0, suggesting a potential 65.85% downside.</li>
<li>Analysts currently favor an Neutral trajectory for Definitive Healthcare, with an average 1-year price target of $3.4, suggesting a potential 80.65% downside.</li>
<li>Analysts currently favor an Buy trajectory for OptimizeRx, with an average 1-year price target of $14.17, suggesting a potential 19.35% downside.</li>
</ul>
<h3>Peer Metrics Summary</h3>
<p>In the peer analysis summary, key metrics for Health Catalyst, Definitive Healthcare and OptimizeRx are highlighted, providing an understanding of their respective standings within the industry and offering insights into their market positions and comparative performance.</p>
<p>
<table>
<thead>
<tr>
<th>Company</th>
<th>Consensus</th>
<th>Revenue Growth</th>
<th>Gross Profit</th>
<th>Return on Equity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Simulations Plus</td>
<td>Buy</td>
<td>22.55%</td>
<td>$13.13M</td>
<td>1.64%</td>
</tr>
<tr>
<td>Health Catalyst</td>
<td>Buy</td>
<td>6.28%</td>
<td>$36.23M</td>
<td>-6.40%</td>
</tr>
<tr>
<td>Definitive Healthcare</td>
<td>Neutral</td>
<td>-6.76%</td>
<td>$43.76M</td>
<td>-27.95%</td>
</tr>
<tr>
<td>OptimizeRx</td>
<td>Buy</td>
<td>11.37%</td>
<td>$13.34M</td>
<td>-1.89%</td>
</tr>
</tbody>
</table>
</p>
<p>Key Takeaway:</p>
<p>Simulations Plus ranks at the top for Revenue Growth and Gross Profit among its peers. It is in the middle for Consensus rating. However, it has the lowest Return on Equity compared to its peers.</p>
<h3>All You Need to Know About Simulations Plus</h3>
<p>Simulations Plus Inc is engaged in the software industry. It includes two segments. It develops and produces software for use in pharmaceutical research and education, and provides consulting and contract research services to the pharmaceutical industry. The company's operating segments include Software and services. The company offers software products for pharmaceutical research such as ADMET (Absorption, Distribution, Metabolism, Excretion, and Toxicity). It generates maximum revenue from the software segment. Maximum revenue is earned from USA following EMEA and Asia Pacific.</p>
<h3>Key Indicators: Simulations Plus's Financial Health</h3>
<p><strong>Market Capitalization Perspectives:</strong> The company's market capitalization falls below industry averages, signaling a relatively smaller size compared to peers. This positioning may be influenced by factors such as perceived growth potential or operational scale.</p>
<p><strong>Revenue Growth:</strong> Simulations Plus displayed positive results in 3 months. As of 28 February, 2025, the company achieved a solid revenue growth rate of approximately <strong>22.55%</strong>. This indicates a notable increase in the company's top-line earnings. When compared to others in the Health Care sector, the company excelled with a growth rate higher than the average among peers.</p>
<p><strong>Net Margin:</strong> Simulations Plus's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive <strong>13.7%</strong> net margin, the company effectively manages costs and achieves strong profitability.</p>
<p><strong>Return on Equity (ROE):</strong> The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of <strong>1.64%,</strong> the company showcases effective utilization of equity capital.</p>
<p><strong>Return on Assets (ROA):</strong> Simulations Plus's ROA stands out, surpassing industry averages. With an impressive ROA of <strong>1.54%</strong>, the company demonstrates effective utilization of assets and strong financial performance.</p>
<p><strong>Debt Management:</strong> Simulations Plus's debt-to-equity ratio is below the industry average at <strong>0.0</strong>, reflecting a lower dependency on debt financing and a more conservative financial approach.</p>
<p><a href="https://www.benzinga.com/quote/SLP/earnings"><strong>To track all earnings releases for Simulations Plus visit their earnings calendar on our site.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


Earnings

A Look Ahead: Simulations Plus's Earnings Forecast

<p>Equity Bancshares (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EQBK#NYSE">EQBK</a>) is preparing to release its quarterly earnings on Monday, 2025-07-14. Here's a brief overview of what investors should keep in mind before the announcement.</p>
<p>Analysts expect Equity Bancshares to report an <strong>earnings per share</strong> (EPS) of $0.89.</p>
<p>The market awaits Equity Bancshares's announcement, with hopes high for news of surpassing estimates and providing upbeat guidance for the next quarter.</p>
<p>It's important for new investors to understand that guidance can be a significant driver of stock prices.</p>
<h3>Overview of Past Earnings</h3>
<p>In the previous earnings release, the company beat EPS by $0.02, leading to a 1.25% increase in the share price the following trading session.</p>
<p>Here's a look at Equity Bancshares's past performance and the resulting price change:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q1 2025</strong></th>
<th><strong>Q4 2024</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>0.83</td>
<td>0.92</td>
<td>0.99</td>
<td>0.92</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>0.85</td>
<td>1.04</td>
<td>1.31</td>
<td>0.99</td>
</tr>
<tr>
<td><strong>Price Change %</strong></td>
<td>1.0%</td>
<td>2.0%</td>
<td>2.0%</td>
<td>1.0%</td>
</tr>
</tbody>
</table>
</p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1752242487_0.png" alt="eps graph" /></p>
<h3>Performance of Equity Bancshares Shares</h3>
<p>Shares of Equity Bancshares were trading at $43.41 as of July 10. Over the last 52-week period, shares are up 10.98%. Given that these returns are generally positive, long-term shareholders are likely bullish going into this earnings release. </p>
<p><a href="https://www.benzinga.com/quote/EQBK/earnings"><strong>To track all earnings releases for Equity Bancshares visit their earnings calendar on our site.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


EQBK

A Look at Equity Bancshares's Upcoming Earnings Report

<p>Truist Securities  analyst Michael Ciarmoli   maintains L3Harris Technologies (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LHX#NYSE">LHX</a>) with a Buy and raises the price target from $260 to $279.</p>


Truist Securities Maintains Buy on L3Harris Technologies, Raises Price Target to $279

<p>FB Financial (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FBK#NYSE">FBK</a>) is gearing up to announce its quarterly earnings on Monday, 2025-07-14. Here's a quick overview of what investors should know before the release.</p>
<p>Analysts are estimating that FB Financial will report an <strong>earnings per share</strong> (EPS) of $0.88.</p>
<p>The market awaits FB Financial's announcement, with hopes high for news of surpassing estimates and providing upbeat guidance for the next quarter.</p>
<p>It's important for new investors to understand that guidance can be a significant driver of stock prices.</p>
<h3>Earnings History Snapshot</h3>
<p>During the last quarter, the company reported an EPS beat by $0.02, leading to a 1.97% drop in the share price on the subsequent day.</p>
<p>Here's a look at FB Financial's past performance and the resulting price change:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q1 2025</strong></th>
<th><strong>Q4 2024</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>0.83</td>
<td>0.83</td>
<td>0.79</td>
<td>0.76</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>0.85</td>
<td>0.85</td>
<td>0.86</td>
<td>0.84</td>
</tr>
<tr>
<td><strong>Price Change %</strong></td>
<td>-2.0%</td>
<td>-1.0%</td>
<td>6.0%</td>
<td>8.0%</td>
</tr>
</tbody>
</table>
</p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1752242477_0.png" alt="eps graph" /></p>
<h3>Tracking FB Financial's Stock Performance</h3>
<p>Shares of FB Financial were trading at $47.39 as of July 10. Over the last 52-week period, shares are up 10.71%. Given that these returns are generally positive, long-term shareholders are likely bullish going into this earnings release. </p>
<p><a href="https://www.benzinga.com/quote/FBK/earnings"><strong>To track all earnings releases for FB Financial visit their earnings calendar on our site.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


Earnings Outlook For FB Financial

<p>Whales with a lot of money to spend have taken a noticeably bearish stance on <strong>Vertex Pharmaceuticals</strong>.</p>
<p>Looking at options history for Vertex Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRTX#NASDAQ">VRTX</a>) we detected 11 trades.</p>
<p>If we consider the specifics of each trade, it is accurate to state that 9% of the investors opened trades with bullish expectations and 63% with bearish.</p>
<p>From the overall spotted trades, 6 are puts, for a total amount of $241,517 and 5, calls, for a total amount of $8,715,760.</p>
<h3>Projected Price Targets</h3>
<p>Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $475.0 to $500.0 for Vertex Pharmaceuticals over the recent three months. </p>
<h3>Volume &amp; Open Interest Trends</h3>
<p>In today's trading context, the average open interest for options of Vertex Pharmaceuticals stands at 1663.0, with a total volume reaching 3,306.00. The accompanying chart delineates the progression of both call and put option volume and open interest for high-value trades in Vertex Pharmaceuticals, situated within the strike price corridor from $475.0 to $500.0, throughout the last 30 days.</p>
<h3>Vertex Pharmaceuticals Call and Put Volume: 30-Day Overview</h3>
<p><img src="https://www.benzinga.com/files/images/story/2025/1752242469_0.png" alt="Options Call Chart" /></p>
<h3>Noteworthy Options Activity:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th><strong>Open Interest</strong></th>
<th><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>VRTX</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>06/17/27</td>
<td>$92.0</td>
<td>$85.3</td>
<td>$86.0</td>
<td>$500.00</td>
<td>$3.4M</td>
<td>3.3K</td>
<td>1.1K</td>
</tr>
<tr>
<td>VRTX</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>06/17/27</td>
<td>$88.5</td>
<td>$86.1</td>
<td>$88.5</td>
<td>$500.00</td>
<td>$2.2M</td>
<td>3.3K</td>
<td>513</td>
</tr>
<tr>
<td>VRTX</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>06/17/27</td>
<td>$93.7</td>
<td>$88.2</td>
<td>$88.1</td>
<td>$500.00</td>
<td>$1.3M</td>
<td>3.3K</td>
<td>702</td>
</tr>
<tr>
<td>VRTX</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>06/17/27</td>
<td>$88.7</td>
<td>$84.6</td>
<td>$88.7</td>
<td>$500.00</td>
<td>$887.0K</td>
<td>3.3K</td>
<td>202</td>
</tr>
<tr>
<td>VRTX</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>06/17/27</td>
<td>$96.5</td>
<td>$87.1</td>
<td>$87.0</td>
<td>$500.00</td>
<td>$870.0K</td>
<td>3.3K</td>
<td>100</td>
</tr>
</tbody>
</table>
</p>
<h3>About Vertex Pharmaceuticals</h3>
<p>Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio, and Alyftrek for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex has diversified its portfolio through Casgevy, a gene-editing therapy for beta thalassemia and sickle-cell disease, and Journavx, a non-opioid pain medication approved for the treatment of moderate-to-severe acute pain in adults. Additionally, Vertex is evaluating small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.</p>
<p>Following our analysis of the options activities associated with Vertex Pharmaceuticals, we pivot to a closer look at the company's own performance.</p>
<h3>Where Is Vertex Pharmaceuticals Standing Right Now?</h3>
<ul>
<li>Currently trading with a volume of 93,478, the VRTX's price is down by 0.0%, now at $479.53. </li>
<li>RSI readings suggest the stock is currently may be approaching overbought.</li>
<li>Anticipated earnings release is in 24 days.</li>
</ul>
<h3>Professional Analyst Ratings for Vertex Pharmaceuticals</h3>
<p>A total of 3 professional analysts have given their take on this stock in the last 30 days, setting an average price target of $476.67.</p>
<p><strong>Unusual Options Activity Detected: Smart Money on the Move</strong></p>
<p>Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;adType=benzinga-insights&amp;ad=options-activity&amp;campaign=wallstreetadvantage"><strong>Click here for access</strong></a>.<br />
&#x2A; Consistent in their evaluation, an analyst from RBC Capital keeps a Sector Perform rating on Vertex Pharmaceuticals with a target price of $420.<br />
&#x2A; An analyst from HC Wainwright &amp; Co. downgraded its action to Buy with a price target of $550.<br />
&#x2A; Consistent in their evaluation, an analyst from Morgan Stanley keeps a Equal-Weight rating on Vertex Pharmaceuticals with a target price of $460. </p>
<p>Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for Vertex Pharmaceuticals with <a href="https://www.benzinga.com/pro/">Benzinga Pro</a> for real-time alerts.</p>


Options

Markets

VRTX

Vertex Pharmaceuticals's Options: A Look at What the Big Money is Thinking

Press Releases

Turo and Uber bring peer-to-peer car sharing to Uber Rent

Uber Launches Senior Accounts and Simple Mode Nationwide

Uber Eats and Five Below Partner to Deliver Extreme Value Direct to Doorsteps Nationwide

Wayve and Uber Partner to Launch L4 Autonomy Trials in the UK

DICK'S Sporting Goods and Golf Galaxy Join Uber Eats for On-Demand Delivery

Uber Expands AI Data Platform to Power Next-Gen Enterprise and AI Lab Needs

Serve Robotics Brings Autonomous Robot Delivery to Atlanta with Uber Eats, Shake Shack and Local Favorites

Uber Eats Expands Partnerships with Beloved Local Grocers

Uber Announces Date of Second Quarter 2025 Results Conference Call

Uber Partners with the LA28 Olympic and Paralympic Games and Team USA as the Official Rideshare and On-Demand Delivery Partner to Help Games Stakeholders Go Anywhere and Get Anything

FIVE

SERV

SHAK

UBER

Avis Budget Gr

Grab Holdings Limited - Class A Ordinary Shares

Grab Holdings

Hertz Global Holdings, Inc - Common Stock

Hertz Global Holdings

Lyft

Marti Technologies, Inc. Class A Ordinary Shares

Marti Technologies

Ryde Group

Swvl Holdings

Webus International Limited - Ordinary Shares

Webus International

B of A Securities

Wells Fargo

Canaccord Genuity

Cantor Fitzgerald

Stifel

Screenshot 2024-11-07 at 6.41.21 PM

Emerging Markets

Movers & Shakers

DASH

Innovation Beverage Group Offers Zero-Alcohol Range As Non-Alcoholic Beverages Market Grows

Screenshot 2024-11-06 at 6.42.32 PM

ABNB

TZUP

This Ad-Tech Platform Pays Consumers To Recommend Products On Their Social Media, Effectively Doing What Airbnb And Uber Did In A New Industry

Screenshot 2024-08-28 at 5.36.32 PM

Fintech news covering the emerging Financial Technology services sector

Comments

Uber Technologies

Actualités

Dernières nouvelles pour Uber Technologies (NYSE:UBER) Stock

Les gens regardent aussi

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL